- New state-of-the-art centre to scale up COVID-19 vaccine and gene therapy manufacturing gets £100m investment
- Additional £4.7m for new training facilities and an online learning platform to boost vaccine as well as cell and gene therapy skills
- New centre and skills vital for the UK’s ability respond to diseases like coronavirus, and potential future pandemics
The 2020 annual report released today presents Cell and Gene Therapy Catapult's achievements, collaborations and initiatives from the past year and their impact in enhancing growth, productivity and supporting the development and commercialisation of cell and gene therapies.
European law firm Fieldfisher has advised finnCap and Zeus Capital, in their capacities as joint brokers to AIM-listed Avacta Group plc, a leading life sciences company, on its heavily oversubscribed £48 million fundraising to develop a saliva-based rapid antigen COVID-19 test.
The collaboration will see Achilles Therapeutics expand their manufacturing footprint at the CGT Catapult manufacturing centre to supply clinical trials of their novel T cell therapy products. Onboarding has begun into one of the newly operational modules at the state-of-the-art facility.
Fieldfisher are delighted to announce that their pan-European Life Sciences sector group have mobilised to show support for life science companies contributing efforts towards global pandemic COVID-19.
By Annie Zeng
Gene therapy is an experimental and therapeutic technique involving the engineering of genes with the hope to cure disease at its root cause. This has become an increasingly buoyant area for investment and although still at an early phase of development, there have been recent approvals of clinical and commercial gene therapies for use in humans.
Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering with respiratory disease, today announced it has appointed Dr David Morris MD as Chief Medical Officer to lead the Company’s respiratory programmes.